Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Vaccines. 2009 Dec;8(12):1663-79. doi: 10.1586/erv.09.123.

Currently approved prophylactic HPV vaccines.

Author information

1
Department of Community and Family Medicine, University of Missouri-Kansas City School of Medicine, 7900 Lee's Summit Road, Kansas City, MO 64139, USA. diane.m.harper@gmail.com

Abstract

Cervarix and Gardasil are two prophylactic HPV vaccines designed primarily for cervical cancer prevention. Cervarix is effective against HPV-16, -18, -31, -33 and -45, the five most common cancer-causing types, including most causes of adenocarcinoma for which we cannot screen adequately. Gardasil is effective against HPV-16, 18 and 31, three common squamous cell cancer-causing types. In addition, Gardasil is effective against HPV-6 and -11, causes of genital warts and respiratory papillomatosis. The most important determinant of vaccine impact to reduce cervical cancer is its duration of efficacy. To date, Cervarix's efficacy is proven for 6.4 years and Gardasil's for 5 years.

PMID:
19943762
DOI:
10.1586/erv.09.123
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center